6505--2027-2028 Influenza Virus Vaccine

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NAC PHARMACEUTICALS (36E797)

Contract Value

Not provided

Codes & Classification
Solicitation Number

36E79726R0035

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

UNITED STATES

SourceSAM
Documents2
The Department of Veterans Affairs, through its NAC Pharmaceuticals office, has issued a solicitation for the supply of Influenza Virus Vaccine for the 2027-2028 influenza season. This procurement seeks to secure pre-filled, single-dose syringes equipped with a plunger and Luer lock needle attachment. The vaccines must be either Trivalent or Quadrivalent formulations, specifically designed to be latex and preservative free, and suitable for administration to individuals aged 36 months and older. The scope of this contract encompasses the manufacturing and delivery of pharmaceutical-grade influenza vaccines, aligning with NAICS Code 325412 (Pharmaceutical Preparation Manufacturing). The primary objective is to ensure the timely availability of safe and effective influenza immunization options for eligible recipients across the United States, supporting the health and wellness initiatives of the Department of Veterans Affairs. Key requirements include the provision of vaccines in pre-filled syringes, adherence to latex and preservative-free standards, and compatibility with Luer lock needle attachments. The deliverables must meet all regulatory and quality standards for pharmaceutical products intended for persons aged 36 months and above. Contractors are expected to demonstrate robust manufacturing capabilities, quality assurance processes, and reliable distribution networks to fulfill the contract requirements. The contracting entity is NAC Pharmaceuticals (36E797), a federal office within the Department of Veterans Affairs. The place of performance is within the United States, and the opportunity is classified under Product Service Code 6505, which pertains to drugs and biologicals. Interested parties may direct inquiries to the primary contact, Deb Fassl, via email at [email protected] or by phone at 708-786-5894. This solicitation is currently active, with a posting date of August 9, 2026, and a response deadline of September 23, 2026. Contractors should review the full solicitation and associated attachments available on SAM.gov (Opportunity ID: 9e06051f05fa435d8f866aa1d267ca46) for detailed instructions and requirements. No specific set-aside or special considerations are noted in the provided information. Overall, this opportunity is well-suited for pharmaceutical manufacturers with proven experience in vaccine production and distribution, particularly those capable of meeting stringent quality and safety standards for government healthcare programs.